| Similar Articles |
|---|
 |
The Motley Fool
April 15, 2009
Brian Orelli |
Johnson & Johnson Still Withstands Recession While Johnson & Johnson is big, it has proven to be agile during the recession, and this quarter was no different.   |
The Motley Fool
March 6, 2009
Brian Orelli |
Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now? |
The Motley Fool
March 18, 2009
Selena Maranjian |
Better Than a Penny Stock Why take on big risks with penny stocks when you don't have to? |
The Motley Fool
February 2, 2007
Ryan Fuhrmann |
Uncertain Outlook on CVS Has the retail pharmacy bit off more than it can chew? Investors may soon look back longingly to the day when CVS focused as much on organic, or internal, means to grow its business as it does on acquisitions to buy outside market share. |
The Motley Fool
March 11, 2009
Selena Maranjian |
Taxed Twice and Still a Good Deal If you think it's not fair that so much of your income gets lopped off by Uncle Sam and his friends at the IRS, you probably won't be thrilled to know that your dividend income gets taxed twice. It's true, though. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
March 26, 2010
Cathy Applefeld Olson |
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup. |
The Motley Fool
October 2, 2011
Shubh Datta |
Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment? |
The Motley Fool
August 1, 2007
Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
May 4, 2011
Jason Knapp |
Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will. |
The Motley Fool
May 2, 2008
Timothy M. Otte |
CVS Caremark and the Snickers Factor The soft economy has hit some retail sectors hard. But there are still pockets of life, and CVS Caremark is one of the companies leading the way. |
The Motley Fool
August 31, 2011
Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool
April 22, 2009
Alyce Lomax |
McDonald's Defies the Recession The fast-food giant continues to lure consumers to its discount fare. |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
May 8, 2007
Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results. |
The Motley Fool
February 27, 2009
Dan Caplinger |
5 Great Ways to Trim Your Taxes Here are the five best things you can do to trim your taxes, both now and in the future. |
The Motley Fool
March 9, 2009
Alyce Lomax |
Are the Golden Arches Tarnished? McDonald's says first-quarter earnings will be pressured due to currency translation. |
The Motley Fool
March 19, 2009
Selena Maranjian |
I Made Another Bone-Headed Move One Motley Fool investor honestly explains how he lost 50% of his International Paper investment in just one month. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
May 3, 2007
Joe Magyer |
The Weekly Dividend Could your portfolio use a Band-Aid? PepsiCo... Arch Coal... Dow Chemical... Johnson & Johnson... etc. |
The Motley Fool
March 22, 2010
Dave Mock |
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. |
The Motley Fool
November 5, 2007
Timothy M. Otte |
CVS Is in the Zone Pharmacy giant CVS grew EPS by 36% in the third quarter. The company has been on a roll since its merger with Caremark last year. |
The Motley Fool
August 8, 2006
Selena Maranjian |
4 Blue-Chip Bargains Have you noticed? Some big and beautiful companies are selling at attractive prices. Wal-Mart... Home Depot... PepsiCo... Johnson & Johnson... |
The Motley Fool
October 22, 2010
Roger Friedman |
3 Health-Care Stocks for Your Watchlist There's money to be made in health care. But finding the right plays, especially among health care providers, can prove confounding. |
The Motley Fool
August 28, 2010
Todd Wenning |
Dividend Report Card: Johnson & Johnson Does this health-care titan's dividend pass the test? |
The Motley Fool
September 23, 2010
Russ Krull |
10 Core Stocks for Your Portfolio: McDonald's McDonald's stock deserves to be on investors' menus. |
The Motley Fool
November 4, 2009
Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool
January 31, 2008
Claire Stephanic |
Safe Stocks During a Downturn Why consumer-related dividend-paying stocks can keep you out of the poorhouse in a recession. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
June 2, 2011
Dee Gill |
CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up? |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
April 13, 2009
Brian Orelli |
Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion. |
The Motley Fool
October 6, 2011
Dan Caplinger |
Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year. |
The Motley Fool
February 23, 2009
Brian Orelli |
The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor. |
The Motley Fool
August 23, 2010
Jacob Roche |
Bond Investors Got a Fever -- and the Only Prescription Is More Yield Desperate for yield, bond investors start taking anything they can get. |
The Motley Fool
August 3, 2007
Ryan Fuhrmann |
CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations. |
The Motley Fool
January 8, 2009
Jeff Fischer |
5 Stocks for Strong Income Boost your returns in any market with these stocks: 3M... Johnson & Johnson... McCormick & Co. ... PepsiCo... Conoco Phillips... |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
November 9, 2006
Shruti Basavaraj |
The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio. |
The Motley Fool
February 4, 2008
Timothy M. Otte |
CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer. |
The Motley Fool
April 15, 2009
Brian Orelli |
Abbott's on Sale Abbott isn't firing on all cylinders the way it was last year, but things still look fine, and the stock is selling at a discount right now. |
The Motley Fool
December 18, 2008
Selena Maranjian |
Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
February 25, 2009
Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
